Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers inc...
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong ...
Novartis (NYSE:NVS) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.89 by 4.23 p...
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the tre...
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches ...
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, re...
Jefferies analyst Peter Welford maintains Novartis (NYSE:NVS) with a Buy and raises the price target from $121 to $122.5.
